Cover Image
市場調查報告書

老年性黃斑部病變 (AMD) 與其他視網膜疾病:全球治療藥物市場 2016-2026年

Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026

出版商 Visiongain Ltd 商品編碼 290418
出版日期 內容資訊 英文 169 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老年性黃斑部病變 (AMD) 與其他視網膜疾病:全球治療藥物市場 2016-2026年 Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
出版日期: 2016年02月29日 內容資訊: 英文 169 Pages
簡介

全球視網膜疾病治療藥物市場規模、預計2020年將達173億8,000萬美元。2016年至2020年預計將達成更強大的收益。

本報告針對老年性黃斑部病變 (AMD) 等視網膜疾病藥物市場進行調查、銷售動向、技術動向、市場機會等收益預測、2次市場 (濕型AMD、乾型AMD、DR (糖尿病視網膜症) ) 動向。

第1章 調查概要

第2章 全球老年性黃斑部病變 (AMD) 與其他視網膜疾病市場

  • 視網膜疾病是什麼
  • 視網膜疾病種類
  • AMD與其他視網膜疾病診斷、治療
  • 約2億人患有AMD?
  • 1億人以上換有DR (糖尿病視網膜症)
  • 最初的RVO (視網膜靜脈阻塞症) 推計有1,600萬患者人口
  • Eylea是市場領導治療藥物
  • Regeneron的市場比例很高
  • 市場最大的疾病領域是?

第3章 視網膜疾病市場2次市場

  • 濕型AMD依然是市場主要收益來源
  • 濕型AMD:血管產生過程明確的定義了藥物標的
  • 乾型AMD:阻止視網膜色素上皮 (RPE) 細胞損壞或無效的需求
  • DR (糖尿病視網膜症) :以糖尿病黃斑浮腫 (DME) 為目標的臨床矚目焦點
  • Lucentis 、 Eylea 延長試驗在其他新領域有可能性
  • 全面預測

第4章 老年性黃斑部病變 (AMD) 與其他視網膜疾病市場認證產品

  • 現在的產品將獨佔市場到2026年
  • Lucentis:市場第2大治療藥物
  • Eylea:位居首位?
  • Avastin:未被正式承認但最常使用的產品
  • Visudyne (Valeant/Novartis): 調查對像期間中ゾ賣上ゎ減少エペ見迂ノ
  • Jetrea (ThromboGenics/Novartis): 2013年ソ發賣ゾ期待外ホ

第5章 濕型AMD臨床實驗

  • 主要臨床實驗候補藥物
  • Fovista (Ophthotech Corporation/Novartis) :下個重點?
  • 臨床實驗目標其他成長因素
  • Conbercept (Chengdu Kanghong Biotech):
  • 新抗VEGFR劑輸送系統是必要的嗎?
  • 活性抗炎症技術化的新輸送系統
  • 濕型AMD藥物開發研究中的其他目標
  • 再生醫療技術

第6章 乾型AMD臨床實驗

  • 乾型AMD明顯進步的是哪項?
  • MC-1101 (MacuCLEAR)
  • ACU-4429 (Acucela)
  • 乾型AMD補體抑制方面的希望
  • 副腎皮質類固醇 (皮質類固醇) :以乾型AMD症等炎症為目標
  • 神經防護作用:現代醫療最困難的問題之一
  • 再生醫療:乾型AMD最大疾病目標之一
  • 乾型AMD其他治療法

第7章 糖尿病性視網膜症 (DR) 臨床實驗

  • Ozurdex/Posurdex (Allergan) :為一般DME患者通過認可
  • Lucentis:DR的挑戰?
  • 新型抗VEGF
  • DR開發中類固醇
  • DR開發中的其他製品

第8章 地區市場分析

  • 最有可能擴大收益的市場
  • 美國:視網膜疾病大型市場
  • 日本:安定的市場可能性
  • 歐洲5國:高齡化帶動市場成長
  • BRIC各國:市場最大的成長牽引者

第9章 產業、市場定性分析

  • 強勢
  • 弱點
  • 機會
  • 威脅
  • 社會
  • 技術
  • 經濟
  • 政治

第10章 調查問卷

第11章 結論

  • Lucentis老舊化:接近終點?
  • Lucentis vs. Eyla vs. Avastin:抗VEGF市場3種方向性
  • 濕型以外的適應重要性增加
  • 乾型市場具有極大可能性
  • Fovista是臨床實驗候補中最有希望的
  • 視網膜疾病依舊是眼疾主要分野

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0093

AMD and Other Retinal Diseases - our new study reveals trends, R&D progress, and predicted revenues

Where is the AMD and Other Retinal Diseases market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 169 page report provides 50 tables and 42 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AMD and Other Retinal Diseases market. See how to exploit the opportunities.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
  • Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
    • Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
    • Philip G. Ralston, Jr., MacuCLEAR.

image1

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those eye drug revenues?

How will individual retinal medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of five prominent brands:

  • Lucentis
  • Eylea
  • Avastin
  • Visudyne
  • Jetrea.

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 10 leading national markets from 2016-2026:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

image2

There you will find countries with the highest revenues and potential growth. You can explore the outlook for treating ocular problems, serving doctors' and patients' needs. Assess the opportunity and ways to help people retain eyesight. Discover what the commercial prospects are for you and your organisation.

image3

Leading companies and the potential for market growth

Our analyses forecasts the world market for retinal drugs will reach $17.38bn in 2020. It will achieve strong revenue expansion from 2016 to 2026. Our report reveals how high sales will go.

You can also see which companies hold the most potential. Examine eye drug developers, producers and marketers, including these firms:

  • Novartis
  • Roche
  • Regeneron
  • Bayer
  • Santen
  • Valeant
  • Allergan

Research and development - assess innovation, trends and possibilities

There you can also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:

  • Combination therapies, including neovascularisation disrupters
  • Angiogenesis inhibition by blocking pericyte recruitment
  • Anti-inflammatory mechanisms (inc. corticosteroids)
  • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
  • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:

  • Oligonucleotides and siRNA therapy
  • Anti-integrin oligopeptide treatment
  • Complement factor inhibition and serotonin modifiers
  • Angiotensin receptor blockers and converting enzyme inhibitors
  • Biosimilars and other follow-on biologicals and next generation therapeutics
  • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

The R&D holds strength, variety and promise. See what's possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.

How the AMD and Other Retinal Diseases report helps you

  • Revenues for retinal disease treatments to 2026 - assess the overall world drugs market's potential and receive forecasted revenues for treating wet age-related macular degeneration (wAMD), dry AMD, diabetic retinopathy (DR) and other disorders
  • Products' sales to 2026 - discover the predicted revenues of Lucentis, Eylea, Avastin, Visudyne and Jetrea, seeing how those medicines can compete and succeed
  • National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
  • R&D activities - see the progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities
  • Companies, news and opinions - examine the participants, including Roche, Novartis, Bayer, Regeneron and Allergan, and receive two exclusive interviews, helping your reputation for insight and staying ahead
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantage.

Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.

Discover predictions for rear-eye medicines, getting information to help you now With our independent analyses explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that market data means you're less likely to fall behind in knowledge or miss a crucial opportunity. Through your choice find how you could save time and effort, also benefiting your authority, reputation and results.

Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2025 for retinal pharmaceuticals. So avoid missing out - please order the report now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. World AMD and Other Disease Market, 2015

  • 2.1 What are Retinal Diseases?
  • 2.2 Types of Retinal Diseases
  • 2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
  • 2.4 Nearly 200 Million People with AMD?
  • 2.5 Over 100 Million with DR
  • 2.6 First RVO Estimates Suggest Patient Population of 16 Million
  • 2.7 Market to Make Rapid Pace to 2026
  • 2.8 Eylea Became Leading drug in the Market
  • 2.9 Regeneron the Leading Presence in the Market
  • 2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2015

  • 3.1 Wet AMD Still the Main Source of Revenue in the Market
  • 3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
    • 3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
  • 3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
    • 3.3.1 Dry AMD Segment to Emerge in the Forecast Period
  • 3.4 DR: Coming Into Clinical Focus, with DME the Main Target
    • 3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
  • 3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
  • 3.6 Projections for All Segments, 2015-2026

4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026

  • 4.1 Will the Current Products Dominate the Market Through 2026?
  • 4.2 Lucentis: Second Leading Drug in the Market
    • 4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
    • 4.2.2 Shadow of Avastin Still Hangs Over Lucentis
    • 4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
    • 4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
    • 4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
    • 4.2.6 Improving Cost and Compliance for Lucentis
    • 4.2.7 Lucentis Revenue Forecast 2015-2026
    • 4.2.8 Will Loss of Physician Goodwill Harm Lucentis' Growth?
  • 4.3 Eylea: Holds the Throne?
    • 4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
    • 4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
    • 4.3.3 First Wave of Eylea's Expansion Finally Beginning to Break?
    • 4.3.4 Eylea into DME and Other New Indications
    • 4.3.5 Eylea Revenue Forecast 2015-2026
    • 4.3.6 How Far Can Eylea's Momentum Carry It?
  • 4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
    • 4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
    • 4.4.2 Judicial Review Averted in the UK by Price Adjustment
    • 4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
    • 4.4.4 Roche and Novartis Challenge CATT's Headline Conclusions
    • 4.4.5 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
    • 4.4.6 Avastin Revenue Forecast, 2015-2026
    • 4.4.7 Will Anything Dislodge Avastin from its Central Position?
  • 4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
    • 4.5.1 Visudyne Revenue Forecast, 2015-2026
  • 4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
    • 4.6.1 Jetrea Revenue Forecast, 2015-2026

5. Pipeline for Wet AMD Segment, 2015-2026

  • 5.1 The Leading Pipeline Candidates
  • 5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
    • 5.2.1 Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
    • 5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
    • 5.2.3 Ophthotech Partners with Novartis for Fovista
    • 5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
    • 5.2.5 The Move toward Combination Therapies
  • 5.3 Other Growth Factor Targets in the Pipeline
    • 5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    • 5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
    • 5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
    • 5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
  • 5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
    • 5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
    • 5.4.2 Binding Affinity Comparable to Eylea
  • 5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
    • 5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
    • 5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
    • 5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
    • 5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
    • 5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
    • 5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
  • 5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
    • 5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
    • 5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
  • 5.7 Other Targets Under Investigation in wAMD Drug Development
    • 5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
    • 5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
    • 5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
    • 5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
    • 5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
    • 5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
    • 5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
    • 5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
    • 5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
    • 5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
  • 5.8 Regenerative Medicine Approaches
    • 5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
    • 5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
    • 5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2015-2026

  • 6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
  • 6.2 MC-1101 (MacuCLEAR): Leading the Pack?
    • 6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
    • 6.2.2 Novel Endpoints in Phase 3 Study
    • 6.2.3 Can MacuCLEAR Make It?
  • 6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
    • 6.3.1 Data Expected in July 2016
    • 6.3.2 Other Visual Cycle Modulators
  • 6.4 High Hopes for Complement Inhibition in Dry AMD
    • 6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
    • 6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
  • 6.5 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
    • 6.5.1 Iluvien (Alimera Sciences): Study terminated
    • 6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
  • 6.6 Neuroprotection: One of Modern Medicine's Holy Grails
    • 6.6.1 Tandospirone (Alcon): Not effective in GA
    • 6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
    • 6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
    • 6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
  • 6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
    • 6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
    • 6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    • 6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
    • 6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
    • 6.7.5 First iPSC Trial in Japan in Dry AMD Patients
    • 6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
  • 6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2015-2026

  • 7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
  • 7.2 Lucentis: The Game Changer for DR?
  • 7.3 New Anti-VEGF Additions
    • 7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
  • 7.4 Steroids in Development for DR
    • 7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
    • 7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
    • 7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
    • 7.4.4 Cortiject (Santen): Prodrug Candidate
    • 7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
  • 7.5 Other Products in Development for DR
    • 7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    • 7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
    • 7.5.3 TriLipix (Abbott): No New Development for Promising Drug
    • 7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
    • 7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

8. Regional Market Breakdown, 2015-2026

  • 8.1 Which Markets Hold the Most Revenue Growth Potential?
  • 8.2 The US: Leading Market for Retinal Diseases
  • 8.3 Japan: Strong Market Potential
  • 8.4 EU5: Ageing Populations to Drive Market Growth
  • 8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2016-2026

  • 9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
  • 9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
  • 9.3 Opportunities: New Markets and R&D Synergies
  • 9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
  • 9.5 Social: Low Diagnosis, Low Compliance
  • 9.6 Technological: Innovation for the Eye
  • 9.7 Economic: Off-Label Treatment and Reimbursement Issues
  • 9.8 Political: The Demography and Diabetes Challenges

10. Research Interviews

  • 10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
    • 10.1.1 Major Changes in AMD and Other Retinal Diseases Market
    • 10.1.2 The Landscape of Emerging Markets
    • 10.1.3 Opportunities and Plans of Marken's Network
    • 10.1.4 DR Market Opportunities
  • 10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
    • 10.2.1 MC-1101: Progress in Clinical Trials
    • 10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
    • 10.2.3 Partnerships and Expected Launch of MC-1101

11. Report Conclusions

  • 11.1 The Age of Lucentis: Nearing Its Conclusion?
  • 11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
  • 11.3 Indications Outside Wet AMD to Gain in Importance
  • 11.4 Dry AMD Market Has Huge Potential
  • 11.5 Fovista Most Prominent Among the Pipeline Candidates
  • 11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2015
  • Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2015
  • Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
  • Table 3.3 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.4 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
  • Table 3.5 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.6 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
  • Table 3.7 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.8 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
  • Table 3.9 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 3.10 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 3.11 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2015, 2020 and 2026
  • Table 4.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
  • Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
  • Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2012-2015
  • Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
  • Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 4.9 Lucentis: Revenue ($bn), AGR (%), 2013-2014
  • Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 4.12 Avastin: Revenue ($bn), AGR (%), 2012-2014
  • Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 4.17 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.18 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 5.1 Selected R&D Pipeline for wAMD, 2015
  • Table 6.1 Selected R&D Pipeline for Dry AMD, 2015
  • Table 7.1 Selected R&D Pipeline for DR, 2015
  • Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
  • Table 9.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
  • Table 9.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
  • Table 9.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2026

List of Figures

  • Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2015-2026
  • Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2015
  • Figure 2.3 Market Breakdown by Company: Market Share (%), 2015
  • Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
  • Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
  • Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2015
  • Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2015
  • Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2015-2026
  • Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2015-2026
  • Figure 3.5 DR Segment Forecast: Revenue ($bn), 2015-2026
  • Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015-2026
  • Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015, 2020 and 2026
  • Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2020
  • Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2026
  • Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
  • Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
  • Figure 4.3 Market Forecast by Product: Revenue ($bn), 2015-2026
  • Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2015, 2020 and 2026
  • Figure 4.5 Lucentis: Revenues Forecast ($bn), 2015-2026
  • Figure 4.7 Eylea Forecast: Revenue ($bn), 2015-2026
  • Figure 4.8 Drivers and Restraints for Eylea, 2015
  • Figure 4.9 Avastin Forecast: Revenue ($bn), 2015-2026
  • Figure 4.10 Drivers and Restraints for Avastin, 2015
  • Figure 4.11 Visudyne Forecast: Revenues ($bn), 2015-2026
  • Figure 4.12 Jetrea Forecast: Revenues ($bn), 2015-2026
  • Figure 8.1 Regional Breakdown: Revenue ($bn), 2015-2026
  • Figure 8.2 Regional Breakdown: Revenue ($bn), 2015, 2020 and 2026
  • Figure 8.3 Regional Market Share (%), 2015
  • Figure 8.4 Regional Market Share (%), 2020
  • Figure 8.5 Regional Market Share (%), 2026
  • Figure 8.6 US Market: Revenue ($bn), 2015-2026
  • Figure 8.7 Japan: Revenue ($bn), 2015-2026
  • Figure 8.8 EU5: Grouped Revenue ($bn), 2015-2026
  • Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2015-2026
  • Figure 8.10 EU5 Breakdown: Market Share (%), 2015
  • Figure 8.11 EU5 Breakdown: Market Share (%), 2020
  • Figure 8.12 EU5 Breakdown: Market Share (%), 2026
  • Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2015-2026
  • Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2015-2026
  • Figure 8.15 Market Share (%) within BRIC Group by Country, 2015
  • Figure 8.16 Market Share (%) within BRIC Group by Country, 2020
  • Figure 8.17 Market Share (%) within BRIC Group by Country, 2026

Companies Listed

  • Abbott
  • Acucela
  • Alcon
  • Aldexa
  • Alimera Sciences
  • Alkeus Pharmaceuticals
  • Allegro
  • Allergan
  • Allergan and Molecular Partners
  • Ampio Pharmaceuticals
  • Association for Research in Vision and Ophthalmology
  • Avalanche Biotechnologies
  • Bayer Healthcare
  • Biotime
  • Biovail Corporation
  • Bristol-Myers Squibb
  • Casey Eye Institute
  • Chengdu Kanghong Biotech
  • Colby Pharmaceutical
  • Columbia University
  • CoMentis
  • Eli Lilly
  • EyeGate Pharmaceuticals
  • Eyetech
  • FDA
  • ForSight Vision4
  • Genentech
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • GlaxoSmithKline (GSK)
  • iCo Therapeutics
  • Icon Bioscience
  • International Diabetes Federation
  • Italian Competition Authority (ICA)
  • Japanese Ministry of Health, Labour and Welfare
  • Lpath, Inc.
  • MacuCLEAR
  • Mesoblast
  • MSD
  • Neuron Systems Inc.
  • Neurotech
  • NHS
  • NICE
  • Novartis
  • Novo Nordisk
  • Ocata Therapeutics
  • OHR Pharmaceutical
  • Ophthotec Corporation
  • Ora Bio
  • Oregon Health and Science University
  • Othera Pharmaceuticals
  • Oxford BioMedica
  • Oxigene
  • PanOptica
  • Pfizer
  • QLT
  • Regeneron
  • ReVision Therapeutics
  • Roche
  • Santen Pharmaceutical
  • Sirion Therapeutics
  • StemCells
  • Stemedica Cell Technologies
  • ThromboGenics
  • Tyrogenex
  • UCB
  • UK's General Medical Council
  • University College London (UCL)
  • US National Eye Institute
  • Valeant Pharmaceuticals
  • Varinel
  • VisionCare Ophthalmic Technologies
  • Vitreoretinal Technologies
  • WHO
  • Xcovery Group
  • Xcovery Vision
Back to Top